tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s Obefazimod
PremiumRatingsPromising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s Obefazimod
19d ago
Abivax price target raised to $114 from $95 at Citizens JMP
Premium
The Fly
Abivax price target raised to $114 from $95 at Citizens JMP
24d ago
One new option listing on September 18th
Premium
The Fly
One new option listing on September 18th
1M ago
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
PremiumCompany AnnouncementsAbivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
2M ago
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: A Potential Game-Changer?
Premium
Company Announcements
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: A Potential Game-Changer?
2M ago
Abivax price target raised to $112 from $70 at Piper Sandler
Premium
The Fly
Abivax price target raised to $112 from $70 at Piper Sandler
3M ago
Abivax $400M Spot Secondary; price range $62.50-$65.00
PremiumThe FlyAbivax $400M Spot Secondary; price range $62.50-$65.00
3M ago
Abivax announces $400M ADS offering
Premium
The Fly
Abivax announces $400M ADS offering
3M ago
Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
Premium
The Fly
Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100